Decentralized Clinical Trials (DCTs) represent a paradigm shift from traditional clinical trial models. Unlike conventional clinical research trials, which require participants to visit research or medical centers, DCTs leverage digital health technologies, such as telehealth visits and/or home health visits to conduct trials remotely. This approach not only enhances participant convenience, making clinical trials more accessible, efficient, and patient centric, but also broadens the reach of clinical research studies.
Since the onset of the COVID-19 pandemic in 2020, there has been a significant increase in the adoption of decentralized elements in clinical research trials. The FDA, for example, has approved study design elements and/or protocol amendments to include DCT components, recognizing the need for flexibility and participant safety. This shift has led to an increase in the number of clinical research trials incorporating remote monitoring, telehealth visits, and remote clinical trial procedures.
Hybrid vs. Fully Remote DCT Models
- Hybrid DCTs: This model combines elements of traditional and decentralized clinical research trials. Participants may still visit clinical research sites for certain procedures, such as initial screenings or complex interventions, while other aspects of the trial, such as follow-up visits and data collection, are conducted remotely. This model offers a balance between the familiarity of traditional trials and the convenience of remote participation. This model is more common for many early phase, gene therapy, or other clinical research trials that require imaging, more careful safety monitoring, or more intricate dosing regimens.
- Full Remote DCT: In this model, all trial activities are conducted remotely, with no need for participants to visit clinical sites. Digital health technologies, such as wearable devices, telemedicine, and mobile apps, are utilized to collect data, monitor patient health, and facilitate communication between participants and researchers. This model maximizes convenience and accessibility, particularly for patients with mobility issues or those living in remote areas.
The Advantages of DCTs
Decentralized clinical trials offer meaningful benefits for both participants and sponsors by reducing logistical barriers and improving data efficiency.
Improved Recruitment, Retention, and Compliance
Remote participation makes it easier for participants to take part and stay engaged in a clinical research trial. This convenience supports higher enrollment and stronger retention, improving trial completion rates and overall study performance.
Reduced Participant and Caregiver Burden
Allowing visits and assessments to occur at home or near home lessens the demands placed on participants and their caregivers. This is especially important for those with chronic conditions or individuals requiring frequent assistance, as it reduces travel time and disruption to daily routines.
Expanded Access
Participants with mobility challenges, rare diseases, or access to clinical trial sites often struggle to participate in traditional site-based studies. Elements of DCTs can remove many of these barriers, enabling broader participation and generalizability of clinical trial results.
Shorter Timelines
Real-time data capture, remote monitoring, and streamlined processes may also accelerate clinical trial timelines, helping bring therapies to market more quickly.
Challenges and Considerations
- Technology Access and Literacy: Older participants or those lacking internet access or devices may need technical support to participate in DCTs. Ensuring that all participants have the necessary tools and knowledge to engage with digital health technologies is crucial.
- Oversight Complexity: Sponsors must supervise additional vendors, when utilizing home health vendors. Investigators also need to oversee remote health clinicians to ensure participant safety and limit data collection variability, which creates additional site burden.
- Operational Coordination: Managing multiple locations, vendors, and data systems adds logistical complexity. Effective coordination and communication are vital to ensure the smooth operation of decentralized trials.
The Future of Clinical Trials
The FDA’s guidance on Conducting Clinical Trials with Decentralized Elements (2024) clarifies that trials with decentralized components are still held to the same standards as traditional trials even though it offers flexibility for how these elements are implemented through telehealth, home health visits, and local providers for clinical trial procedures. Realizing their full potential will require:
- Intentional protocol design — protocols, protocol amendments, and informed consent documents that incorporate remote visits, procedures, and data capture.
- Technology validation — making sure the devices and systems used in remote data collection are reliable, secure, and appropriate for the study population.
- Participant planning — building in support for participants who may lack digital resources or experience.
- Robust ethical and regulatory oversight — ensuring that data privacy and participant safety are protected in decentralized environments. Updating or creating Standard Operating Procedures (SOPs) for remote source document collection and storage, and safety monitoring. Ensuring home health clinicians are added to the delegation of authority logs (DOAs) and 1572, where required.
